PUBLISHER: The Business Research Company | PRODUCT CODE: 1810926
PUBLISHER: The Business Research Company | PRODUCT CODE: 1810926
Intranasal corticosteroids are anti-inflammatory drugs administered through the nose to treat conditions like allergic rhinitis and nasal polyps. They work by reducing swelling, congestion, and mucus production in the nasal passages, thereby improving breathing and alleviating allergy symptoms.
The main categories of intranasal corticosteroids include prescription and over-the-counter drugs. Prescription intranasal corticosteroids are doctor-approved medications used to manage moderate to severe allergic rhinitis or chronic nasal inflammation, often favored for long-term or specialized treatment under medical guidance. These drugs are applied to treat allergic rhinitis, nasal polyps, sinusitis, and related conditions. They are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are utilized by a range of end users including hospitals, clinics, homecare settings, and healthcare providers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The intranasal corticosteroids market research report is one of a series of new reports from The Business Research Company that provides intranasal corticosteroids market statistics, including intranasal corticosteroids global market size, regional shares, competitors with intranasal corticosteroids market share, detailed intranasal corticosteroids market segments, market trends and opportunities, and any further data you may need to thrive in the intranasal corticosteroids industry. The intranasal corticosteroids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The intranasal corticosteroids market size has grown strongly in recent years. It will grow from $6.29 billion in 2024 to $6.78 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. Growth during the historic period can be attributed to the rising prevalence of allergic rhinitis, an increasing incidence of chronic sinusitis, greater awareness of non-oral treatment options, expanded use in pediatric allergic conditions, and improved availability of over-the-counter intranasal products.
The intranasal corticosteroids market size is expected to see strong growth in the next few years. It will grow to $9.07 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. Growth in the forecast period is expected to be driven by an increasing focus on minimally invasive therapies, a rising incidence of allergic diseases linked to climate change, growing preference for self-administered treatments, wider adoption of combination intranasal therapies, and enhanced digital health support for allergy management. Key trends during this period include the integration of smart devices for dose monitoring, innovations in preservative-free nasal sprays, development of pediatric-friendly formulations, advancement of steroid-free adjunct therapies, and the incorporation of e-health platforms for treatment tracking.
The growing prevalence of allergic rhinitis is expected to drive the expansion of the intranasal corticosteroids market in the coming years. Allergic rhinitis is an allergic reaction that causes inflammation in the nasal passages, usually triggered by airborne allergens like pollen, dust mites, mold, or pet dander. This condition is becoming more common primarily due to increasing environmental pollution, which exposes people to allergens and irritants that provoke allergic responses in the nasal passages. Intranasal corticosteroids work by reducing inflammation in the nasal passages, alleviating symptoms such as sneezing, congestion, and runny nose. For example, in October 2023, the National Library of Medicine reported that allergic rhinitis affects over 400 million individuals globally, with prevalence rates ranging from 10% to 30% in adults and exceeding 40% in children. Therefore, the rise in allergic rhinitis cases is boosting the intranasal corticosteroid market.
Key players in the intranasal corticosteroids market are developing innovative formulations like nasal sprays to improve targeted drug delivery and enhance patient adherence. Nasal sprays administer liquid medication directly into the nose via a spray nozzle to treat allergies, congestion, or inflammation. They facilitate rapid drug absorption through the nasal mucosa, providing quick relief while minimizing systemic side effects. For instance, in March 2024, OptiNose Inc., a US pharmaceutical company, gained FDA approval for XHANCE, the first treatment specifically indicated for adults with chronic rhinosinusitis (CRS) without nasal polyps. This nasal spray features a unique exhalation delivery system that allows the medication to penetrate deeply into the nasal cavity, effectively managing CRS with or without nasal polyps in adults. Each spray delivers 93 mcg of fluticasone propionate, and the device works by having the user blow into a mouthpiece while simultaneously releasing the spray into the nostril, ensuring precise delivery and improved symptom relief.
In April 2023, SK Capital Partners LP, a US-based investment firm, acquired Apotex for an undisclosed sum. This acquisition aims to strengthen Apotex's global standing in affordable pharmaceuticals by supporting growth, enhancing operational efficiency, and fostering product innovation. Apotex Inc. is a Canada-based manufacturer of intranasal corticosteroid sprays.
Major players in the intranasal corticosteroids market are GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Haleon plc, Intas Pharmaceuticals Limited, Organon Pharma (UK) Limited, Sun Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Limited, Cipla Ltd., Hikma Pharmaceuticals plc, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, OptiNose US Inc., Taro Pharmaceutical Industries Ltd., Maya Biotech Private Limited, AdvaCare Pharma USA, Lupin Ltd., Xenone Healthcare Private Limited.
North America was the largest region in the intranasal corticosteroids market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intranasal corticosteroids report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the intranasal corticosteroids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The intranasal corticosteroids market consists of sales of fluticasone propionate nasal spray, mometasone furoate nasal spray, budesonide nasal spray, beclomethasone dipropionate nasal spray, and triamcinolone acetonide nasal spray. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Intranasal Corticosteroids Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on intranasal corticosteroids market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for intranasal corticosteroids ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The intranasal corticosteroids market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.